On Friday 14 September and over the weekend that followed, a social media post and related media coverage from the charity Children with Cancer UK called for the supplement melatonin to be made available to children and young people with cancer on the NHS

Families now know their very sick child will be able to have the best treatment that gives the greatest chance of long-term survival here in the UK.

Following the recent provisional decision by the National Institute for Health and Care Excellence (NICE) not to approve dinutuximab beta (Qarziba™) for use on the NHS in England and Wales, we have updated our briefing document.

From Solving Kids’ Cancer, Neuroblastoma UK, the Children’s Cancer and Leukaemia group, JACK, The Bradley Lowery Foundation, Hugs from Henry, Christopher’s Smile, Niamh’s Next Steps and Smile with Siddy.

A NICE committee hearing will be held on 11th April to discuss whether or not to recommend dinutuximab beta antibody therapy for NHS use. An application has been received from pharmaceutical company EUSA Pharma (who hold the European and UK licence).

We’re delighted to let you know that we’re now working with the St George’s Society of New York who will provide a helping hand for families whose children are having therapies such as immunotherapy clinical trials.

In the UK, the first meeting of the National Institute for Health and Care Excellence (NICE) to appraise dinutuximab beta was held on 23rd November in Manchester.

We are delighted to announce another significant award from GamesAid – a charity which supports children’s charities in the UK.

Solving Kids’ Cancer has been working since 2015 to ensure continued availability of, and access to, antibody therapy.